AG真人官方

DICE Therapeutics, Inc. (NASDAQ: DICE) is a distinguished biopharmaceutical company renowned for leveraging its proprietary DELSCAPE technology platform to develop groundbreaking oral therapeutic candidates. Founded with a vision to revolutionize chronic disease treatment in the realm of immunology, DICE is dedicated to creating advanced oral treatments for autoimmune and inflammatory conditions.

The company's core technology, DELSCAPE, is designed to discover selective oral small molecules that can modulate protein-protein interactions (PPIs) as effectively as systemic biologics. This innovation is aimed at providing patients with convenient oral alternatives to traditional injectable therapies. DICE's lead therapeutic candidates include oral antagonists for the pro-inflammatory signaling molecule IL-17, which is a validated drug target implicated in a variety of immunological disorders.

DICE's notable projects include the development of oral IL-17 inhibitors such as DC-806 and DC-853, currently in clinical development, aimed at treating conditions like psoriasis and other autoimmune diseases. Additionally, the company is advancing oral therapeutic candidates targeting the integrin 伪4尾7 for the treatment of inflammatory bowel disease, showcasing its commitment to addressing significant unmet medical needs.

In a strategic move to bolster its capabilities and market presence, DICE recently entered into a definitive agreement to be acquired by Eli Lilly and Company (NYSE: LLY) for approximately $2.4 billion. This acquisition underscores the potential and value of DICE's innovative approaches and proprietary technology. Eli Lilly's extensive resources and global reach are expected to enhance the development and commercialization of DICE's therapeutic pipeline, accelerating the availability of these transformative treatments to patients worldwide.

Financially, the acquisition represents a premium of about 40% to DICE's 30-day volume-weighted average trading price, reflecting strong market confidence in DICE's future prospects. The transaction, approved by the boards of directors of both companies, is anticipated to close in the third quarter of 2023, pending customary closing conditions and regulatory approvals.

With a team of dedicated experts and a robust pipeline of oral therapeutics, DICE Therapeutics stands at the forefront of innovation in immunology, poised to make significant strides in improving patient outcomes for chronic and debilitating diseases.